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Abstract
Fibrogenesis is usually initiated when regenerative processes have failed and/or chronic inflammation occurs. It is
characterised by the activation of tissue fibroblasts and dysregulated synthesis of extracellular matrix proteins. FHL2
(four-and-a-half LIM domain protein 2) is a scaffolding protein that interacts with numerous cellular proteins,
regulating signalling cascades and gene transcription. It is involved in tissue remodelling and tumour progression.
Recent data suggest that FHL2 might support fibrogenesis by maintaining the transcriptional expression of alpha
smooth muscle actin and the excessive synthesis and assembly of matrix proteins in activated fibroblasts. Here, we
present evidence that FHL2 does not promote bleomycin-induced lung fibrosis, but rather suppresses this process by
attenuating lung inflammation. Loss of FHL2 results in increased expression of the pro-inflammatory matrix protein
tenascin C and downregulation of the macrophage activating C-type lectin receptor DC-SIGN. Consequently, FHL2
knockout mice developed a severe and long-lasting lung pathology following bleomycin administration due to
enhanced expression of tenascin C and impaired activation of inflammation-resolving macrophages.
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Introduction
Fibrosis is a consequence of the excessive expression and
deposition of extracellular matrix (ECM) components, which
can result in sclerosis and scarring of tissues. Fibrotic changes
usually take place when regenerative processes have failed or
long-term inflammation occurs [1–4]. During acute inflammation
and tissue damage, the affected cells release large amounts of
bioactive lipids and inflammatory factors that induce the
proliferation of surrounding cells, and also attract and activate a
large number of immune cells and fibroblasts in order to repair
the injured tissue. Activated myofibroblasts are the major
source of newly synthesised fibrous connective tissue, with
transforming growth factor beta (TGFβ) being the major
profibrotic cytokine and activator of myofibroblasts [5,6].
Idiopathic pulmonary fibrosis is a progressive and fatal
fibrosing disease of the lung with unknown aetiology, but
several environmental factors such as smoking, chronic
microaspiration or viral infection are known to promote its
development [7,8]. The disease is characterized by damage of
interstitial tissue and myofibroblast transdifferentiation with
exaggerated accumulation of ECM proteins leading to scarring
of alveolar compartments of the lung where gas exchange
occurs [4,8,9]. Available data increasingly indicate that chronic
inflammation and aberrant wound healing play an important
role in the development of the disease [8–11].
Bleomycin (BLM) is a chemotherapeutic drug with a serious
side effect - the development of lung fibrosis [12]. Its
intratracheal application in mice induces a transient but severe
expansion of lung fibrosis that resembles fibrotic changes in
humans to a certain degree, and is currently one of the best
established animal models of lung fibrosis [12–14]. The
mechanism of BLM-induced lung disease is complex and still
insufficiently understood. As a cytostatic drug, it induces DNA
strand brakes, resulting in the inhibition of cell proliferation and
cell lysis [12]. However, BLM can also cause alveolar cell
damage independently of its effect on DNA by inducing lipid
peroxidation and increasing the apoptosis of epithelial and
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endothelial cells, leading to alveolar oedema and lung
inflammation [13,14]. The acute lung tissue injury and ongoing
inflammation are believed to be the major reason for activation
and recruitment of myofibroblasts and fibrotic alterations.
FHL2 is a scaffolding protein that can interact with numerous
membranes, as well as cytosolic and nuclear proteins [15]. By
forming a protein complex with integrins and focal adhesion
kinase, FHL2 supports the clustering of integrins and integrin-
driven assembly of matrix proteins [16]. By interaction with
cytosolic proteins FHL2 is involved in regulation of NF-κB and
MAPK signalling cascades [17–20]. In addition to modulating
signalling molecules, FHL2 shuttles between the cytosol and
nucleus, acting as a cofactor in the transcription of αSMA
(alpha smooth muscle actin) and some matrix proteins, but
inhibiting the expression of matrix metalloproteinases [21–23]
During skin wound healing, FHL2 is upregulated in activated
fibroblasts, but only transiently [24]. Pro-fibrotic cytokines such
as TGFβ and S1-P (sphingosine 1-phosphate) induce its
expression, while the pro-inflammatory cytokine IL-1
downregulates FHL2 [19,25].
The purpose of this work was to study the potential
supportive effect of FHL2 on the development of BLM-induced
lung fibrosis. Surprisingly, after administering BLM, FHL2-
deficient mice developed more severe lung pathology than wild
type (WT) mice.
Materials and Methods
Bleomycin (BLM) treatment
All animal experiments were approved by the local ethics
committee and performed in strict accordance with the German
regulations of the Society for Laboratory Animal Science (GV-
SOLAS) and the European Health Law of the Federation of
Laboratory Animal Science Associations (FELASA). The
protocols were approved by the Landesamt für Natur, Umwelt
und Verbraucherschutz Nordrhein-Westfalen (LANUV-NRW),
Germany. WT and FHL2-KO mice (genetic background
C57Bl/6 [26]) were kept in pathogen-free conditions and two- to
four-month-old mice were used. Before BLM (B2434, Sigma-
Aldrich) application, animals were anaesthetised by an i.p.
injection of 200 μl of a ketamine-rompun solution (equal
amounts of a 2% rompun solution and a 10% ketamine solution
were mixed at the ratio of 1:10) and weighed. BLM dissolved in
PBS was applied intranasally. Usually a dosis of 2 U/kg of
mouse body weight was applied, if not indicated otherwise.
Following BLM administration the body weight was recorded
twice a week during the course of the experiment. For lung
analysis, animals were euthanized on different days after BLM
application and the right lungs were usually fixed with 4 %
paraformaldehyde for histological studies and the left lungs
were minced and homogenised either in RIPA buffer for protein
analysis or in RNAlate solution for qRT-PCR studies. For in
vivo depletion of macrophages, mice were intravenously
injected with clodronate-liposomes (purchased from
ClodronateLiposomes.com, The Netherlands) or PBS-
liposomes as control (100 µl/mouse). The next day, they were
repeatedly injected with 75 µl/mouse of clodronate-liposomes
or PBS-liposomes solution, but intranasally. On the following
day, the mice received BLM intranasally and 5 days later, they
received another dose of 75 µl/mouse of clodronate- or PBS-
liposomes intranasally.
Isolation, stimulation and transfection of peritoneal
murine macrophages
To increase the number of isolated peritoneal macrophages,
mice received 0.8 ml of 4% frozen and thawed starch gel in
PBS intraperitoneally (i.p.) three days before stimulation. The
cells were washed out from the abdominal cavities of
euthanized mice with 5 ml of sterile PBS. Cells from three to
four animals were pooled and washed twice with PBS by
centrifugation at 1200 rpm for 5 min at 4°C, after which they
were resuspended in DMEM with 2% foetal calf serum (FCS)
and 50 µg/ml gentamicin, and plated into 6-well dishes with
2x106 cells per dish. After incubation at 37°C in a humidified
incubator under 5% CO2 for 2-3 h, the non-adherent cells were
washed off with PBS and the remaining attached macrophages
were stimulated with lipopolysacharide (LPS, 1µg/ml) or BLM
(15 U/ml) and mouse lung tissue lysate (containing
carbohydrates) for an additional 24 h.
To obtain lung lysates, lungs from two WT mice were
minced, placed in 5 ml of PBS, repeatedly frozen in liquid
nitrogen four times and thawed in a 37°C-water bath, before
being sonicated on ice three times for 30 seconds each and
centrifuged. The supernatant was then filtered sterile and used
for stimulating macrophages at a dilution of 1:100. The optimal
dilution was determined in preliminary experiments. The lung
lysate was used as a source of released endogenous damage-
associated molecular pattern molecules.
For FHL2 rescue experiments, suspensions of freshly
isolated peritoneal macrophages were transfected with the
pCS2+MT plasmid containing the human myc-tagged FHL2 or
with empty vector using the Amaxa apparatus and the Amaxa
Mouse Macrophage Nucleofector Kit (Lonza, Cologne,
Germany), following the manufacturer's instructions. For each
transfection set, 1x106 cells and 2 µg of plasmid DNA were
used. After transfection, the cells were incubated for 2-3 hours
at 37°C in 6-well plates and after a medium change, they were
stimulated with 1 µg/ml of lipopolysaccharide (LPS) or 15 U/ml
of BLM and mouse lung lysate for an additional 24 h.
FHL2 knockdown using siRNA
To suppress endogenous FHL2 in fibroblasts, the cells were
transfected for 24 h with 5 nM of specific siRNA using the
HiPerFect transfection kit from Qiagen (Hilden, Germany). As
control, a scrambled RNA probe was used.
Collection of bronchoalveolar lavage fluid (BALF),
sircol collagen and hydroxyproline assays
BALF was collected from euthanized mice after intratracheal
application of 0.5-ml PBS supplemented with 2 mM of EDTA.
To remove the cells, the samples were centrifuged at 400xg for
10 minutes at 4°C. The supernatant was aliquoted and frozen
at -80°C until analysis. Approximately 90% of the total instilled
volume was consistently recovered. The collagen content in
BALF was measured using the Sircol Soluble Collagen Assay
Kit (Biocolor Ltd., UK), following the manufacturer's
FHL2 in Lung Fibrosis
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instructions. The hydroxyproline content of left lungs was
measured by a colorimetric method according to Edwards and
O’Brien [27]. For analysis of immune cells present in BALF, the
lung wash procedure was repeated three times and the
aliquots were combined.
Analysis of lung immune status
A single lung cell suspension was obtained by enzymatic
digestion. The lung tissue was cut into tiny pieces and
incubated in RPMI 1640 medium containing 0.7 mg/ml
collagenase A and 100 Kunitz-units/ml DNase I for 60 min at
37°C. The digested tissue was then passed through a “filter-
cartridge” to remove large pieces of tissue and centrifuged at
400xg for 7-10 min at 4°C. The pellet was resuspended with
erythrocyte lysis buffer and immediately centrifuged and
resuspended again in FACS-PBS (5% FCS in PBS) for flow
cytometry. At least 2x106 cells for each staining analysis were
used. Unstained cells were always used as controls. For
staining, cells were resuspended and incubated in FACS-PBS
containing primary Abs for 20 min on ice, washed twice with
FACS-PBS, and further incubated, if needed, with
fluorochrome-conjugated secondary antibodies for an
additional 20 min. After washing the cells, measurements were
performed with a FACS Calibur flow cytometer. The antibodies
used were: FITC-rat-anti-mouse CD45.2; FITC-rat-anti-mouse
CD11b; biotin-labelled rat-anti-mouse Gr-1 and APC-
streptavidin (purchased from BD Biosciences); as well as APC-
hamster-anti-mouse CD11c; APC-rat-anti-mouse CD8a, PE-
rat-anti-mouse CD4, PE-rat-anti-mouse-MHCII and FITC- or
PE-rat-anti-mouse F4/80 and FITC- or PE-rat-anti-mouse Ly6G
(obtained from eBiosciences). For intracellular staining with
rabbit-anti-S100A9 serum, the fixation/permeabilization kit from
BD Biosciences was used.
qRT-PCR
From cultured eukaryotic cells total RNA was isolated using
the Qiagen RNeasy® Mini kit (Qiagen, Hilden), while from
homogenized lung tissue, total RNA was extracted with the
TRIzol reagent (Roche Diagnostics, France), in accordance
with the manufacturer’s recommendations. RNA integrity was
controlled by an Agilent Bioanalyser 2100 (Agilent
Technologies, Böblingen, Germany) and transcribed into cDNA
using the high-capacity cDNA reverse transcription kit from
Applied Biosystems (Darmstadt, Germany). The mRNA levels
were determined by TaqMan qRT-PCR using the LightCycler
480 II (Roche Diagnostics, Mannheim, Germany). Each cDNA
probe was analysed in triplicate and specific signals were
scored in relation to the signals of two housekeeping gene
transcripts, Cytochrom C and GAPDH. The primers used were
assigned using the Universal ProbeLibrary Assay Design
Centre at www.roche-applied-science.com/.
SDS-PAGE Western blot
RIPA lysates of mouse lung tissues (20 µg/sample) were
resolved by 7% or 10% SDS-PAGE and, after electroblotting
onto a nitrocellulose membrane, proteins were detected by
Western blotting with appropriate antibodies using the ECL
detection system. The rabbit-anti-collagen type I antibody was
purchased from Merck Chemicals GmBH, Schwalbach,
Germany. The rabbit-anti-collagen type III was from Santa Cruz
Biotechnology, Inc. and the rat-anti-tenascin C from Abcam
Inc., Cambridge, UK. Rabbit-anti-fibronectin, mouse-anti-αSMA
and mouse-anti-β actin were from Sigma-Aldrich,
Taufenkirchen, Germany. The mAb anti-FHL2, clone F4B2-B11
and rabbit anti-laminin gamma 1 have been described
elsewhere [16]. The n-fold of protein expression was performed
densitometrically as the relative intensity of the appropriate
protein bands to the loading controls. Values at time point 0
were taken as unity.
Reporter gene assay
HEK 293 cells were co-transfected with the reporter plasmid
pGL3-hTNC-luc (300 ng) and indicated plasmids (1000 ng)
using polyethylenimine. Each transfection was carried out in
triplicate. Relative light units were measured 24 h after
transfection using the Luciferase Assay System (Promega,
Madison, WI, USA) and were normalised to protein
concentrations of cell lysates. The human TNC promoter
comprised a 2000-bp long sequence, including the TATA box
and the first 83 bp of the first exon. pCS2+MT-mycFHL2[1/2-4]
full length as well as the pCS2+MT-mycFHL2[1/2-2] and
pCS2+MT-mycFHL2[3,4] C-terminal and N-terminal truncations
containing the LIM domains ½ to 2 and LIM domains 3 to 4,
respectively, are described in [28]. Transfection of cells with
pcDNA3-HA-MKL1 full-length (FL) or MKL1 truncated
dominant-negative (DN) constructs [29] was used as positive
and negative control, respectively, for TNC promoter activity.
Histological analysis
Paraffin sections of lung specimens were deparaffinised and
stained according to standard protocols with haematoxylin and
eosin or with AZAN trichrome stains according to Heidenhein.
The extent of lung fibrosis was determined by morphometry
according to the Ashcroft criteria, as described in [30]. Usually,
4 different sections per mouse sample were quantified. All
analyses were performed by three independent observers
(A.A., C.N. and T.S.) in a blinded fashion. For the
immunohistochemistry, paraffin sections were dewaxed,
blocked with 10% FBS and incubated with rat-anti-tenascin C
(ab6346, Abcam Inc., Cambridge, UK), rat-anti-F4/80 (CI:A3-1,
Serotec, Oxford, UK) or rabbit-anti-FHL2 (ab66399, Abcam
Inc., Cambridge, UK) antibodies for 1 h at room temperature. A
Vectastain ABC-AP Kit from Vector Laboratories was used to
visualise the stained proteins.
Statistical analysis
Data are expressed as mean+/-SEM unless specified
otherwise. Statistical analysis was performed using the Mann-
Whitney U test and GraphPad Prism software (version 5) with
P values <0.05 regarded as statistically significant and *
P<0.05, ** P<0.01, *** P<0.001. In the following N describes
independent biological experiments, whereas n accounts for
the number of animals analysed per group.
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Results
Development of BLM-induced lung fibrosis
To analyse the potential role of FHL2 in the development of
lung fibrosis, WT and FHL2-deficient mice were first treated
with different doses of BLM to compare their sensitivity to the
drug. Unexpectedly, the FHL2-KO mice showed a higher
mortality rate than WT mice following BLM treatment. At 5 U/kg
BLM, almost 50% of FHL2-negative animals died during the
first 10 days of drug application, while the vast majority of WT
mice survived the treatment (Figure S1A). The higher
sensitivity of FHL2-/- mice to the antibiotic was also reflected by
the stronger loss and slower recovery of body weight after a
single application of BLM at a low dose (Figure S1B). To
determine whether the observed differences corresponded with
dissimilar pulmonary aberrations, we performed a comparative
histological analysis of WT and FHL2-deficient lungs at various
time points after BLM application. The H&E staining of lung
sections showed a clear increase in the swelling of alveoli and
interstitial tissues, as well as an accumulation of infiltrating cells
in both WT and knockout mouse lungs (Figure 1A, upper
panel). These alterations were transient and reached the
maximum in both types of mice two weeks after BLM
application, which is in agreement with published data [14].
Staining of serial lung sections with AZAN trichrome showed
that the observed alterations were accompanied in both WT
and FHL2-null lungs by an increased expression of connective
tissue, indicating that the lung changes were mainly of a fibrotic
nature (Figure 1A, lower panel). A detailed comparison of lung
sections showed that areas occupied by connective tissue
were larger in FHL2-KO lungs than in WT lungs, especially at
early and late times of BLM administration, suggesting a
different progression/regression of fibrotic alterations in the two
types of mice. Quantification of lung fibrosis according to the
Ashcroft criteria [30] confirmed the difference in the
development of fibrosis between WT and KO animals, further
revealing that the fibrotic changes were highly significantly
different between the two groups at an early time of BLM
application, but reached similar levels after two weeks and
declined significantly faster in WT mice (Figure 1B). Newly
synthesized and deposited collagens represent a large part of
connective tissue during fibrosis and quantification of their
content is generally used for evaluating tissue fibrosis. The
most common methods used thereby are the Sircol Collagen
Assay and the hydroxyproline quantification. During lung
fibrosis the protein amount per se, and that of collagens in
particularly, increases not only in the lung tissue but also in the
bronchoalveolar space and changes in their amounts are often
used to characterize fibrotic alterations [31–33]. Measuring
collagen amounts in bronchoalveolar lavage fluids (BALF)
showed a significant increase after BLM treatment in WT and in
FHL2-/- mice as well, but the revealed differences between the
mouse lines were minimal (Figure 1C). Also at day 10 of BLM
treatment no significant differences could be measured, despite
large differences in lung morphology, estimated by Ashcroft
criteria (Figure 1B). Similar results were obtained when the
hydroxyproline content in lungs was used as a measure for
fibrotic changes. Also here the hydroxyproline content in 10- or
14-days treated lungs significantly differed from untreated
controls but the alterations in both mouse strains were similar.
Although both Sircol and hydroxyproline methods revealed
similar results, measuring the collagen content in BALF
revealed a larger difference between control and BLM-induced
mice than the hydroxyproline assay did, suggesting a different
sensitivity of these methods. Furthermore, different methods
used here for assessment of fibrotic changes showed that
evaluation of lung pathology according to Ashcroft criteria after
H&E or trichrome staining encompasses more than just
alterations in expression or deposition of collagens.
Interestingly, our analyses revealed that the lungs of the non-
treated control FHL2-/- mice already displayed some fibrotic
properties (Figure 1A and 1B). Although a large variability
between individual animals was observed (Figure 1E-G),
FHL2-KO lungs generally displayed a denser lung structure
with a stronger expression of connective tissue in the interstitial
spaces (Figure 1A). Ashcroft values (Figure 1E) and the
amounts of Sircol-measured collagens in BALF (Figure 1 F)
confirmed this observation but not the hydroxyproline
measurement (Figure 1G), which might be due to differences in
the sensitivity of methods used.
Expression of ECM proteins during BLM-induced lung
fibrosis
Fibrotic alterations are usually paired with excessive
expression and deposition of different extracellular matrix
proteins, not only collagens. Therefore, we compared
alterations in activity of genes coding for ECM proteins and
alterations in ECM protein amounts in the lungs of WT and
FHL2-KO mice after BLM treatment by qRT-PCR and Western
blot. Consistent with fibrotic scores shown in Figure 1, an
increase in transcriptional activity of ECM genes and an
accumulation of matrix proteins was seen in both WT and
FHL2-KO mice (Fig. 2A, Fig. S2 and S3). However, no large
differences between the two mice strains in the increase of the
most analysed transcripts were detected. Nevertheless, a
general trend towards a higher deposition of ECM proteins in
FHL2-KO lungs was seen, with collagen type III and particularly
tenascin C (TNC) showing a stronger and long-lasting
appearance (Fig. 2A and Fig. S3A). To confirm these results
we compared the amounts of ECM proteins in lungs of WT and
FHL2-KO mice, loading samples of both lung types on the
same gel. Ten-days-long BLM-treated mice were analysed.
Protein quantification of these blot images confirmed the
observed trend, namely a higher protein accumulation in FHL2-
KO lungs, with collagen type III and tenascin C being the most
prominent (Fig. S3B). The stronger and long-lasting presence
of tenascin C in FHL2-KO lungs compared with WT lungs was
also confirmed by immunohistochemistry (Fig. 2B). Altogether,
these data were in good agreement with the histological, Sircol
and hydroxyproline analyses. They confirmed that connective
tissue proteins were induced in the lungs of both WT and KO
mice, with a trend to a stronger deposition and/or slower
resolution in FHL2-KO lungs. Specifically distinguishing was
the behaviour of TNC, a protein that is known to be
upregulated in response to inflammation and tissue remodelling
[34], particularly also in the BLM lung fibrosis model [35]. Its
FHL2 in Lung Fibrosis
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Figure 1.  Development of BLM-induced lung fibrosis in FHL2 WT and knockout mice.  (A) FHL2 WT and knockout mice
received a single intranasal application of BLM (2 U/kg) and the right lungs were fixed in 4% paraformaldehyde and embedded into
paraffin. Four-micrometre-thick sections were stained with hematoxylin and eosin (upper panel) or with AZAN trichrome according to
Heidenhain (lower panel). Bar=200 µm. Representative images from N = 2 and n = 5 to 10 (see B) are shown. (B) Lung sections
shown in A were scored for fibrotic alterations according to Ashcroft criteria [30] by three observers in a blinded fashion. N = 2.
Ciphers above the curves represent the numbers of analysed animals per time point, with upper and lower lines showing WT and
FHL2-KO group of mice, respectively. (C and D) Total collagen amount in the bronchoalveolar spaces (C) and hydroxyproline
content in lungs (D) of BLM-treated mice. N = 2 – 3, depending on the time point. Ciphers above the curves represent the numbers
of analysed animals per group of mice. (E - G) Lung fibrosis score (E), collagen amount in BALF (F) and hydroxyproline content (G)
in lungs of non-induced control mice.
doi: 10.1371/journal.pone.0081356.g001
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expression kinetic in FHL2-KO lungs pointed towards a
stronger inflammation at early stages of BLM treatment and a
slower halt of inflammatory and tissue damaging processes at
later stages. To investigate whether FHL2 is a regulator of TNC
expression, we knocked down FHL2 in mouse fibroblasts that
spontaneously express high levels of TNC. This indeed led to
an increase in TNC transcripts (Fig. 2C), proving thus, that
decreased levels of FHL2 increased the levels of TNC
transcripts. Furthermore, FHL2 strongly inhibited TNC promoter
activity when it was co-expressed with a reporter gene
construct containing the tenascin C promoter sequence
upstream of a luciferase gene. Using N-terminal and C-terminal
FHL2 deletion constructs revealed that the entire FHL2 protein
was required for efficient inhibition (Figure 2D and E).
Regulation of the tenascin C promoter by full-length and
truncated forms of the transcriptional coactivator MKL1 [29]
was used as positive and negative control, respectively.
FHL2-deficient mice exhibit a more pronounced
inflammation status in lungs
The enhanced expression of tenascin C in FHL2-KO lungs
pointed towards a higher inflammation state in the lungs of
knockout than in WT animals following BLM induction. To
approve this suggestion, we measured the levels of the
S100A8/A9 heterodimer protein in bronchoalveolar fluid during
the first two weeks of BLM administration, the time amount
during which the major pathological alterations in lungs
occurred (see Figures 1A and B). The S100A8 and S100A9 are
calcium-binding proteins that belong to the group of damage-
associated molecular pattern proteins or alarmins. They are
released by neutrophils and monocytes very early during
inflammation and are increasingly used as biomarkers for
ongoing inflammatory processes, as the amount of released
S100A8/A9 in circulation or tissues correlates very well with the
degree of inflammation [36–39]. Data presented in Figure 3A
show that the amount of soluble S100A8/A9 proteins grew
rapidly after BLM administration, peaking on day 10 and
declining afterwards, suggesting that the major inflammation
phase in both types of mice takes place during this time
interval. Interestingly, the amount of S100A8/A9 proteins was
permanently higher in FHL2-/- mice (Figure 3A). Furthermore,
non-stimulated control FHL2-/- mice already displayed
significantly higher levels of the S100A8/A9 proteins in the
BALF and serum (Figures 3A and B), which is consistent with
increased fibrotic scores measured in lungs of intact FHL2-KO
mice. Given that the absence of FHL2 facilitates a higher
inflammation state and that the BLM-mediated development of
lung fibrosis is driven by acute pulmonary inflammation due to
the high destruction of lung tissue, it is conceivable that the
amount of FHL2 in WT lungs will decrease during lung fibrosis.
Indeed, both qRT-PCR and Western blot analyses of FHL2
mRNA and protein showed that its expression was
downregulated during the early destructive stage of BLM-
treatment, but increased again at later stages (Figures 3C-E).
Taken together, our data indicated that the more severe lung
phenotype observed in FHL2-deficient mice may be based on
the stronger induction of inflammation at the early stages of
BLM application. It is remarkable that FHL2 was downregulated
in WT mice at this stage and that its expression increased
again when the acute inflammation/destruction phase passed
on to the tissue regenerative phase. The mode of FHL2
alteration after BLM-treatment was reversal to that of tenascin
C (Figure 3D).
Immune status of bleomycin-treated lungs
To study changes in the immune response to BLM-mediated
lung tissue injury, we first analysed the increase of the total
amount of immune cells in bronchoalveolar space 10 days after
BLM administration, at the peak of inflammation in both mouse
strains judged by the content of S100A8/A9 proteins in the
BALF (see Figure 3A). The number of extravasated cells
increased, as already published [12–14], and was higher in
FHL2-KO mice compared to WT mice but not significantly
(Figure 4A). Histological analyses showed that the lung-
infiltrating cells were predominantly found in fibrotic areas with
dense parenchyma and large amounts of deposited
extracellular matrix (Figure 1A). Therefore we digested the lung
tissue with collagenase and DNase and analysed single lung
cell suspensions by flow cytometry. In control mice, no
significant differences between WT and FHL2-KO mice in the
number of immune cells were seen (Figure 4B). On BLM
administration, the number of infiltrated immune cells
increased, but only cells of non-lymphoid origin showed a
significant increase, with F4/80-positive cells showing the
largest accumulation (Figure 4B). While the differences in the
amounts of analysed cells between WT and FHL2-KO mice
were only marginal, a tendency towards a larger count of all
analysed cell types in FHL2-KO lungs was nonetheless
present. Macrophages are not only involved in the progression
of inflammation during tissue injury, but also in resolution of the
inflammation at later phases [40,41]. Thus, we analysed the
activation state of infiltrated macrophages. Double staining of
lung cells for F4/80/MHCII markers revealed that macrophages
of FHL2-KO mice expressed decreased levels of MHCII
receptor (Figure 4C). Interestingly, already a lower amount of
F4/80-positive macrophages of control FHL2-KO lungs
expressed MHCII receptor. A more detailed phenotype analysis
of BLM-induced lung macrophages showed that FHL2-deficient
cells indeed failed to activate, as they expressed not only low
amounts of MHCII receptors but also lower amounts of TNFα
and IL-6 (Figure 4D).
FHL2 deficiency abrogates DC-SIGN-mediated
activation of macrophages
To study whether the absence of FHL2 inhibited the
activation of macrophages in general or the observed effect
was specific for BLM-induced lung damage, we isolated
peritoneal macrophages from WT and FHL2-KO mice,
stimulated them in vitro with lipopolysaccharide (LPS), BLM or
lung lysate, and analysed them for activation markers. The
latter stimuli should imitate the situation in the lung after BLM
application (the high lung tissue damage). As the data in Figure
5A and B show, LPS could still activate FHL2-KO
macrophages, but lung lysate could not. BLM alone had no
effect and it also did not enhance the effect of the lung lysate.
LPS is known to stimulate macrophages via binding to the
FHL2 in Lung Fibrosis
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Figure 2.  FHL2 inhibits expression of tenascin C.  (A) FHL2 WT and knockout mice were administered BLM for the indicated
times. The left lung was then lysed with RIPA buffer and 20 µg of total lysates were analysed by Western blotting for the expression
of different proteins. N = 2, n = 5 to 6 per time point, see Figure S3 for details. Lung lysates from three animals per time point are
shown. Equal protein loads were verified by β-actin immunoblotting. (B) Paraffin lung sections of control and BLM-induced mice
were stained for tenascin C (red). Nuclei (blue) were counterstained with haematoxylin. Bar=500 µm. (C) Immortalised embryonal
fibroblasts from C57Bl/6 mice were transfected with scrambled or FHL2-specific siRNA for 24 h and the expression of tenascin C
examined by TaqMan qRT-PCR. N = 3. (D) HEK 293 cells were cotransfected for 24 h with a luciferase reporter gene construct
containing a 2000-bp tenascin C promoter sequence and indicated plasmids and the luciferase activity was then measured. Relative
scores are presented. Mean values of N = 4 shown. (E) The expression of transfected plasmids was verified by Western blotting. A
mixture of anti-myc and anti-actin antibodies was used to visualize FHL2 protein and the loading control β-actin on the same blot
(upper panel). FHL2[1/2-4] represents the full length protein containing aa 1-279. FHL2[1/2-2] and FHL2 [3,4] represent C-terminal
and N-terminal truncations containing the LIM domains ½ to 2 and LIM domains 3 to 4 or aa 1-157 and aa 159-279, respectively,
and are described in [28]. MKL1 FL represent the full-length MKL1 protein and MKL1 DN, the dominant-negative MKL1 protein
truncated at its N-terminal PPEL motifs and C-terminal transactivation domain, described in [29]. The MKL1 proteins were used as
positive and negative control, respectively, for TNC promoter activity.
doi: 10.1371/journal.pone.0081356.g002
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TLR4 receptor [42]. Following lung tissue damage, however,
large amounts of carbohydrates are released, which may
activate macrophages via the type C lectin CD209a (DC-SIGN)
receptor [43]. qRT-PCR analysis of CD209a transcripts
revealed only a marginal expression in non-activated WT and
KO macrophages and its amount was not changed on LPS
stimulation. However, when cells were incubated with lung
lysate or lung lysate plus BLM the transcription of CD209a
increased dramatically, but only in WT macrophages (Figure
5C). Lung analysis also confirmed the negligible expression of
CD209a in FHL2-/- mice, which did not change following BLM
treatment (Figure 5D), suggesting that FHL2 is probably
involved in the transcriptional regulation of CD209a. To test
this, peritoneal macrophages from FHL2-KO mice were
transfected with a plasmid containing human FHL2 cDNA and
stimulated with LPS or lung lysate plus BLM. Analysis of their
phenotype demonstrated that expression of recombinant FHL2,
but not the empty vector, rescued the transcriptional deficiency
of CD209a following stimulation with carbohydrate-rich lung
lysate. As expected, rescue of FHL2 expression had no
influence on LPS-mediated activation of FHL2-KO
macrophages, but significantly improved macrophage
activation by lung lysate and BLM stimulation (Figure 6A-D).
Macrophage depletion aggravates lung fibrosis
To reveal whether macrophages that infiltrate the lung tissue
after BLM induction express the FHL2 protein, we stained
serial lung paraffin sections of 10-days-long induced WT mice
with antibodies to macrophages and FHL2. Images shown in
Figure 7A (left panel) indicate that dense lung areas with
fibrotic features are infiltrated by macrophages and that
macrophages express FHL2. Staining of FHL2-KO lung
sections (right panel) confirmed the specificity of the FHL2
expression. Finally, we investigated to what extent the
inadequate amount of activated macrophages in the lungs of
FHL2-deficient mice accounted for the observed rapid fibrotic
changes. Therefore, the macrophage pools of WT and FHL2-
KO mice were depleted by injection of clodronate-liposomes
(Figure 7B and C) and lung fibrosis was scored after BLM
application (Figure 7D and Figure S4). Ashcroft criteria
revealed a significant increase in lung fibrosis after
macrophage depletion in both WT and FHL2-KO mice, but the
degree of fibrosis was similar in the two groups of animals, thus
showing that successful activation and recruitment of
macrophages into the injured lung was needed to counteract
fibrotic changes.
Figure 3.  FHL2-deficient mice have a higher inflammation status in the lungs.  (A) The content of the S100A8/A9 soluble
proteins was measured in the BALF of mice by ELISA. The number of analysed animals per time point is shown above the columns.
(B) Concentration of S100A8/A9 proteins in the serum of control mice measured by ELISA. (C) FHL2 transcripts in the lungs of
BLM-treated mice were estimated by TaqMan qRT-PCR. The number of animals analysed per time point varied from 6 to 12. (D)
Western blot analysis of FHL2 expression in the lungs of WT mice after BLM-treatment. Representative images of five to six
analysed animals per each time point are shown. (E) Quantification of FHL2 WB images. The FHL2 amount was estimated
densitometrically as the relative intensity of the FHL2 bands compared to those of the loading controls. Values at time point 0 were
taken as unity. N = 2. The number of analysed animals per time point is shown above the curve.
doi: 10.1371/journal.pone.0081356.g003
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Discussion
As an adaptor protein FHL2 is involved in regulation of
numerous cellular functions [15] and although it appears to be
dispensable for normal development [26,44], deficiency in
FHL2 is associated with delayed mesenchymal regeneration.
Previously we showed that failure of FHL2 results in delayed
wound healing due to impaired collagen contraction and cell
migration [24]. Others have shown that FHL2 deficiency
impairs bone remodelling [45,46], epithelial-mesenchymal
transition, liver regeneration and invasion of tumour cells
[17,47,48]. In this study, we showed that the absence of the
adaptor protein FHL2 aggravated BLM-mediated lung fibrosis.
Not the final extent of fibrotic alteration was increased, but its
development at the early acute inflammation phase was
augmented and the resolution of the disease at later stages
was retarded. This was unexpected, as FHL2 has been
reported to positively regulate the expression of collagens type
I and III, and αSMA as well as to promote the assembly of ECM
proteins [16,22,49]. However, no differences in transcriptional
upregulation of ECM genes between WT and FHL2-KO mice,
except for TNC, could be measured by us in lungs upon BLM-
induced fibrosis, but rather a trend to enhanced deposition of
matrix protein and to increased inflammation in lungs of FHL2-
KO mice was observed.
While the exact mechanism of BLM-induced lung fibrosis is
not fully known, data indicate that an acute lung inflammation
plays an important role in this process [3,4]. Following BLM
application, a large amount of tissue damage takes place and
results in the release of damage-associated molecular pattern
Figure 4.  Immune status of WT and FHL2-KO lungs.  (A) Cell count in BALF of control and 10-day BLM-treated mice. N = 4 and
2 for control and BLM-treated mice, respectively, with 3 to 4 mice per group in each experiment. (B) Single cell suspensions of lung
tissue from control or 10-day BLM-treated mice were studied for the indicated surface receptors by flow cytometry. A total of 105
cells per lung were analysed. n = 8 and 9 for control and n = 5 and 6 for BLM-treated WT and FHL2-KO mice, respectively. The
relative mean amount of immune cells presented in the lungs of wild type mice was always assigned a value of 1. (C) Lung cell
suspensions from (B) were analysed for MHCII and F4/80 surface marker. (D) The F4/80-positive macrophages of BLM-induced
mice were further analysed for expression of activation markers: the MHCII receptor and the intracellular TNFα and IL-6 proteins.
doi: 10.1371/journal.pone.0081356.g004
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molecules that initiate a non-infectious immune response.
Neutrophils are the most abundant immune cells that infiltrate
into damaged tissue very quickly after injury and are replaced
soon by macrophages. Together with neutrophils,
macrophages remove the injured tissue debris, release
proinflammatory cytokines but also play an important role in
halting inflammation and initiating the regenerative processes
by releasing cytokine- and chemokine-blunting proteases and
other MMPs [40,50]. Here we demonstrated for the first time
that FHL2 inhibits the transcription of the ECM protein tenascin
C, but encourages the transcription of the C-type lectin
receptor DC-SIGN. Both proteins are tightly connected to
inflammatory processes. While tenascin C expression is very
restricted in normal adult tissues, it is quickly and transiently
upregulated during tissue injury or acute phase inflammation
and a persistent tenascin C expression is often associated with
chronic inflammation [51]. It is known to promote and maintain
inflammation and is increasingly used, along with S100A8/A9
alarmins, as a biomarker for ongoing inflammatory processes
[42,52]. Given that tenascin C and S100A9 positive signals
indicate where inflammation takes place and the level of
inflammation intensity, a stronger inflammation in FHL2-KO
lungs can be concluded. Tenascin C modulates cell adhesion
as well as attraction of immune cells but also stimulates as a
TLR4 ligand the production of proinflammatory cytokines like
TNF and IL-6 by macrophages [53]. Besides TLRs, C-type
lectin receptors contribute essentially to activation of
macrophages [43]. They recognize carbohydrates on
pathogens or endogenously released carbohydrates during
tissue injury and stimulate in concert with TLR4 the NF-κB
signalling cascade resulting in production of proinflammatory
cytokines [54]. The C-type lectin receptor mediated axis of the
NF-κB activation was apparently defective in FHL2-KO
macrophages, as they did not express the DC-SIGN receptor.
While the TLR4-dependent axis of macrophage stimulation was
intact in FHL2-KO cells, judged by LPS stimulation of
macrophages, it was obviously not enough for adequate
activation of these cells on BLM-treatment, as FHL2-KO lung
macrophages expressed reduced amounts of MHCII as well as
TNF and IL-6 (Figure 4). Of note, the absence of DC-SIGN and
the activation deficiency of FHL2-deficient macrophages could
be rescued by overexpression of recombinant FHL2 protein in
these cells (Figure 6). The increased amount of tenascin C
along with insufficient activation of macrophages in the
Figure 5.  FHL2 deficiency abrogates CD209a/DC-SIGN-mediated activation of macrophages.  (A-C) FHL2 WT or knockout
mice were injected i.p. with 0.8 ml of 4% starch in PBS and three days later, peritoneal macrophages isolated from three to four
mice were combined and plated into 6-well plate dishes. After incubation for 2-3 h, the non-adherent cells were washed off with PBS
and the remaining attached macrophages were stimulated with LPS (1µg/ml), BLM (15 U/ml), lung tissue lysate (LL) or BLM+LL for
24 h. After isolation of total RNA, the transcripts of the indicated genes were determined by TaqMan qRT-PCR. Mean values of
three repeated experiments are shown. (D) The mRNA levels of D209a/DC-SIGN in the lungs of WT and FHL2-KO mice were
determined by qRT-PCR (n=4-5 per group).
doi: 10.1371/journal.pone.0081356.g005
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wounded lung tissue of FHL2-KO mice probably accounts for
the increased development and delayed recovery from fibrotic
alterations. Macrophages not only produce inflammation-
supporting cytokines but also play an essential role during
resolution of inflammation. The potential importance of
macrophages in development of lung fibrosis and essentially in
resolution of the lung pathology was recently demonstrated by
Gibbons and colleagues [41]. They showed that depletion of
macrophages during the recovery phase of BLM-induced lung
fibrosis dampens its resolution. Also in renal fibrosis, depletion
of macrophages during the recovery phase of the pathology led
to failure of matrix degradation and persistent scarring [55].
Moreover, myocardial wound healing was impaired when
macrophages have been depleted [56]. These data are in good
agreement with our results showing a delayed recovery of lung
pathology in FHL2-KO mice, the macrophages of which exhibit
an inadequate activation by carbohydrate related damage-
associated molecular pattern molecules. The increase in lung
fibrosis following clodronate-liposome-mediated depletion of
macrophages further supports this conclusion. We used in our
experiments high doses of BLM, which resulted in rapid acute
but not chronic inflammation, and although our experiments did
not differentiate between the action of macrophages during the
acute inflammation and the later resolution phase of lung
fibrosis, they are in line with published data and emphasize the
importance of macrophages for resolution of fibrotic lung
tissue. Furthermore, we provide evidence for the reason of
inadequate activation of FHL2-KO macrophages. We showed
that FHL2 is essential for transcription of the C-type lectin
receptor DC-SIGN on macrophages, the expression of which,
in turn, plays a key role in stimulation of macrophages by
injured lung tissue (Figures 5 and 6). Interestingly, while this
manuscript was under consideration, Dahan and colleagues
reported that Kupffer cells of FHL2-KO mice also displayed a
reduced activation state, producing less TNF and IL-6 during
liver injury resulting in delayed liver regeneration [17].
Figure 6.  Rescue of FHL2 in FHL2-deficient macrophages restores their ability to upregulate the CD209a receptor and to
respond to BLM and lung lysate.  Peritoneal macrophages from FHL2-KO mice were transfected with empty vector or human
FHL2 cDNA, stimulated with LPS or BLM plus mouse lung lysate, and analysed for expression of (A) human FHL2 and (B)
endogenous mouse CD209a, (C) TNFα and (D) IL-6 by TaqMan qRT-PCR. N = 3, with macrophage samples being pooled from
three to four animals in each experiment.
doi: 10.1371/journal.pone.0081356.g006
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Figure 7.  Depletion of macrophages aggravates lung fibrosis.  (A) Immunostaining of 2 µm-thick serial paraffin lung sections of
10-days BLM-treated WT (left panel) and FHL2-KO (right panel) mice for macrophage marker F4/80 and FHL2. Samples were
counterstained with hematoxylin to reveal nuclei (blue). Arrowheads mark several cells with prominent staining of both proteins.
Lower images represent larger magnifications of marked areas of upper images. Bars = 50 µm. (B-D) FHL2 WT and knockout mice
were injected i.v. with 100 µl/mouse of PBS- or clodronate-liposomes. The next day, they repeatedly received 75 µl/mouse of PBS-
or clodronate-liposomes, but intranasally. On the following day, the mice received 3U/kg of BLM intranasally and 5 days later, they
received another dose of PBS- or clodronate-liposomes intranasally. A higher dose of BLM was used to strengthen the acute
inflammation and the impact of infiltrated macrophages. On day 10 after BLM application, the right lungs were fixed in 4%
paraformaldehyde, embedded into paraffin and analysed for the presence of macrophages by immunohistochemistry using the anti-
F4/80 antibody (B) and for fibrotic alterations according to the Ashcroft criteria (D) after H&E staining (Figure S4A). Bars = 100 µm.
Representative images of F4/80 stained lung sections are shown in (B) and F4/80-positive cells that were counted in five
microscopic fields with a size of 0.75 mm2 in each lung sample are presented in (C). Four animals per group were analysed.
doi: 10.1371/journal.pone.0081356.g007
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Supporting Information
Figure S1.  FHL2-KO mice are more severely affected by
BLM treatment than WT mice. (A) WT and FHL2-KO mice
received a single intranasal dose of BLM and were scored for
mortality rate 10 days later. N = 3, 5 and 2 per BLM doses
analysed and cipher over columns show the number of
analysed animals per group. (B) Body weight alterations of WT
and FHL2-KO mice after a single intranasal application (2 U/kg)
of BLM. N = 3 and n = 8 to 10 for each group of mice.
(TIF)
Figure S2.  Changes in transcription of genes coding for
matrix proteins after BLM treatment. FHL2 WT and knockout
mice were left untreated or administered BLM for 10 days. The
left lungs were then lysed and after isolation of total RNA, the
transcripts of the indicated genes were determined by TaqMan
qRT-PCR. Five to six animals per each group were analysed.
(TIF)
Figure S3.  Changes in matrix protein expression after
BLM treatment. (A) FHL2 WT and knockout mice were
administered BLM for the indicated times. The left lungs were
then lysed with RIPA buffer and 20 µg of total lysates were
analysed by Western blotting for the expression of indicated
proteins. The β-actin immunoblot served as loading control.
Relative protein scores are presented, which were estimated
densitometrically as the relative intensity of the appropriate
protein bands to the loading controls. N = 2. Ciphers below the
β-actin curves represent the numbers of analysed animals per
time point, with upper and lower lines showing WT and FHL2-
KO group of mice, respectively. Mean levels of untreated mice
were assigned a value of 1. (B) FHL2 WT and knockout mice
were untreated or administered BLM for 10 days and total
lysates were analysed by Western blotting for indicated ECM
proteins. β-actin served as loading control. The right image
represents protein scores of BLM-treated samples shown on
Western blots on the left. Relative densitometric intensities of
the appropriate protein bands to the loading controls are
shown. Mean levels of WT mice were always taken as unity.
(TIF)
Figure S4.  Depletion of macrophages aggravates lung
fibrosis. FHL2 WT and knockout mice were injected i.v. with
100 µl/mouse of PBS-liposomes or clodronate-liposomes. The
next day, they repeatedly received 75 µl/mouse of PBS- or
clodronate-liposomes, but intranasally. On the following day,
the mice received 3 U/kg of BLM intranasally and 5 days later,
they received another dose of PBS- or clodronate-liposomes
intrasanally. On day 10 after BLM application, the lungs were
fixed, embedded into paraffin and stained with haematoxylin
and eosin (A). Bar = 250 µm. The collagen amount in the BALF
of these mice was measured by the Sircol Collagen Assay (B).
(C) The left lungs were lysed and after isolation of total RNA,
the transcripts of the indicated genes were determined by
TaqMan qRT-PCR. Four animals for each case were analysed.
(TIF)
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